Comparison of the efficacy of topical 0.05% clobetasol propionate and topical 0.1% tacrolimus in the treatment of early-stage mycosis fungoides


AKSU A., ÖZ A., Kaya H. E., Cetinkaya P. O., Kurt B. Ö., ALTUNAY İ.

Archives of Dermatological Research, cilt.318, sa.1, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 318 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1007/s00403-026-04958-0
  • Dergi Adı: Archives of Dermatological Research
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
  • Anahtar Kelimeler: Mycosis fungoides, Topical tacrolimus, Topical clobetasol propionate
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Comparative data on the efficacy of topical therapies in early-stage mycosis fungoides (MF) remain limited. Topical calcineurin inhibitors have been proposed as steroid-sparing alternatives; however, direct comparative evidence is scarce. This retrospective study included 40 patients with stage IA–IB MF treated with either 0.1% tacrolimus ointment (n = 20) or 0.05% clobetasol propionate ointment (n = 20). In the tacrolimus group, 60% of patients achieved complete clinical response (CCR) and 20% achieved partial response (PR), whereas in the clobetasol group, 95% achieved CCR and 5% achieved PR. The median time to CCR was 3.5 months in the tacrolimus group and 2 months in the clobetasol group (p = 0.520). Among patients achieving CCR, relapse occurred in 25% of tacrolimus-treated patients compared with 63.2% in the clobetasol group (Fisher’s exact p = 0.066). Kaplan–Meier analysis showed a trend toward longer relapse-free survival with tacrolimus, although the difference did not reach statistical significance (log-rank p = 0.060). Although clobetasol propionate was associated with higher initial CCR rates, tacrolimus may represent a steroid-sparing therapeutic option in selected patients with early-stage MF.